智飞生物(300122) - 投资者关系活动记录表

Financial Performance - In the first half of 2021, the company achieved a revenue of 13.171 billion yuan, representing an increase of 88.33% compared to the same period last year [1] - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was 1.055 billion yuan, reflecting a growth of 263.73% year-on-year [1] Product Development and Market Strategy - The company collaborated with the Institute of Microbiology, Chinese Academy of Sciences, to develop the ZhiKeWei vaccine, which received emergency use approval in March 2021 [2] - The company is actively expanding its international business, with successful exports of its products to Indonesia, Pakistan, and Uzbekistan [2] - The company’s tuberculosis product matrix includes two approved products, enhancing its "diagnosis, prevention, and treatment" system for tuberculosis [3] Research and Development Investment - In the first half of 2021, the company invested 790 million yuan in research and development, supporting various ongoing projects [3] - The company plans to utilize up to 3 billion yuan of its own funds for cash management and potential acquisitions in technology platforms [3] Sales and Marketing - The company’s marketing team has grown to over 2,500 members, which supports effective execution of marketing strategies and operational plans [4] - The sales expense ratio remained stable compared to the previous year, attributed to product launch timing and market team development [4] Regulatory and Compliance - The company is focused on complying with national vaccination plans and is monitoring the effectiveness of its products against variant strains of the virus [2] - The company is committed to transparency in disclosing performance and regulatory compliance, particularly regarding its partnership with Merck for HPV vaccines [4]